Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-MERS-S Phase I Trial
NCT03615911Phase 1Completed
- Start
- Nov 2017
- Primary completion
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVA-MERS-S in Middle East respiratory syndrome (MERS) (2 cohorts). Primary endpoints: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity, Percentage of Participants Who Experienced an Unsolicited Adverse Event and 3 more. Started Nov 2017; status: completed.
02
Drugs
MVA-MERS-S
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT03615911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615911.